Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 487,834,048
  • Shares Outstanding, K 2,409,295
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 29,302 M
  • EBITDA $ 36,641 M
  • 60-Month Beta 0.36
  • Price/Sales 5.57
  • Price/Cash Flow 15.65
  • Price/Book 6.24

Options Overview Details

View History
  • Implied Volatility 16.77% (+0.30%)
  • Historical Volatility 14.95%
  • IV Percentile 32%
  • IV Rank 19.14%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 3.18 (1.57%)
  • Put/Call Vol Ratio 0.92
  • Today's Volume 15,896
  • Volume Avg (30-Day) 35,306
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 401,157
  • Open Int (30-Day) 401,914
  • Expected Range 198.75 to 205.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.53
  • Number of Estimates 7
  • High Estimate 2.57
  • Low Estimate 2.51
  • Prior Year 2.04
  • Growth Rate Est. (year over year) +24.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
185.12 +9.08%
on 11/10/25
207.81 -2.83%
on 11/26/25
+15.93 (+8.56%)
since 11/05/25
3-Month
173.33 +16.50%
on 09/19/25
207.81 -2.83%
on 11/26/25
+23.50 (+13.17%)
since 09/05/25
52-Week
140.68 +43.54%
on 01/10/25
207.81 -2.83%
on 11/26/25
+52.41 (+35.05%)
since 12/05/24

Most Recent Stories

More News
Johnson & Johnson's INLEXZOâ„¢ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal

JNJ : 201.93 (-0.27%)
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

  New survey reveals Americans overlook eye health—despite its impact on confidence, independence and early disease detection.

JNJ : 201.93 (-0.27%)
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 182.41 (-0.53%)
XLV : 153.26 (-0.42%)
JNJ : 201.93 (-0.27%)
LLY : 1,010.31 (-0.41%)
IBB : 171.16 (-0.55%)
GILD : 121.22 (-1.14%)
REGN : 718.36 (-0.61%)
AMGN : 329.89 (-3.02%)
UNH : 330.91 (-0.77%)
3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

KO : 70.00 (-0.64%)
JNJ : 201.93 (-0.27%)
ABBV : 226.08 (-1.15%)
Is Johnson & Johnson Stock Outperforming the S&P 500?

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

$SPX : 6,870.40 (+0.19%)
JNJ : 201.93 (-0.27%)
LLY : 1,010.31 (-0.41%)
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

XPH : 54.36 (+0.13%)
JNJ : 201.93 (-0.27%)
LLY : 1,010.31 (-0.41%)
3 of My Favorite Index Funds for 2026

If you want accessible, useful, and downright cheap funds to anchor your portfolio, these three index funds can do it better than most.

NVDA : 182.41 (-0.53%)
VHYAX : 43.74 (+0.02%)
JPM : 315.04 (-0.34%)
FUMBX : 10.44 (-0.10%)
JNJ : 201.93 (-0.27%)
XOM : 116.54 (-0.51%)
VYM : 145.21 (+0.07%)
FXAIX : 238.64 (+0.11%)
DVA : 117.39 (+0.09%)
Why GRAIL Stock Could Be Biotech’s Next Big Breakout

Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.

GRAL : 100.98 (-3.56%)
MRK : 99.72 (-1.16%)
JNJ : 201.93 (-0.27%)
PFE : 26.03 (+1.28%)
BMY : 52.15 (+0.38%)
3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

JPM : 315.04 (-0.34%)
PG : 143.45 (-1.31%)
JNJ : 201.93 (-0.27%)
KVUE : 16.93 (-0.35%)
SPY : 685.69 (+0.19%)
DIA : 480.03 (+0.20%)
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA ® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety...

JNJ : 201.93 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 205.96
2nd Resistance Point 204.70
1st Resistance Point 203.32
Last Price 201.93
1st Support Level 200.68
2nd Support Level 199.42
3rd Support Level 198.04

See More

52-Week High 207.81
Last Price 201.93
Fibonacci 61.8% 182.17
Fibonacci 50% 174.24
Fibonacci 38.2% 166.32
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar